Zheng Quan Zhi Xing·2025-08-26 16:23Core Viewpoint - The internal control evaluation report of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. indicates that as of June 30, 2025, the company has maintained effective internal controls over financial reporting and has not identified any significant deficiencies in both financial and non-financial reporting controls [1][2]. Internal Control Objectives - The objective of the internal control system is to ensure legal compliance in management, asset security, accurate financial reporting, and to enhance operational efficiency and effectiveness [2]. Internal Control Evaluation Conclusion - The company concluded that there are no significant deficiencies in financial reporting internal controls as of the evaluation date, and it has maintained effective internal controls in all significant aspects [2][3]. - There are no identified significant deficiencies in non-financial reporting internal controls as of the evaluation date [2][3]. Internal Control Evaluation Scope - The evaluation covered major units, businesses, and high-risk areas based on a risk-oriented principle, including procurement, sales, project management, fund management, asset management, and R&D [3][4]. Internal Control Deficiency Standards - The company has established quantitative and qualitative standards for identifying deficiencies in financial reporting internal controls, with specific thresholds for significant, important, and general deficiencies based on asset and profit amounts [4][5]. - Similar standards are applied for non-financial reporting internal controls, focusing on direct property loss and compliance with laws and regulations [5][6]. Remediation of Internal Control Deficiencies - The company has addressed the majority of identified general deficiencies in financial reporting internal controls during the reporting period [7].